Gilead Sciences 2Q11 2Q Revenues: $2.1 billion (+11%) 2Q Earnings: $746.2 million (+5%) YTD Revenues: $4.1 billion (+1%) YTD Earnings: $1.4 billion (-11%) Comments: Antiviral product sales were up 11% to $1.8 billion in the quarter. Sales of Atripla increased 15% to $822.0 million, sales of Truvada were up 11% to $711.3 million, and sales of Viread increased 5% to $185.7 million. Sales of Letairis were up 22% to $73.6 million. Sales of Ranexa were up 42% to $86.1 million. Royalty, contract ...